mProX™ Human TNFRSF9 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

TNFRSF9, also known as CD137, is a member of the TNF receptor superfamily and is involved in immune responses. Research has shown that TNFRSF9 expression is higher in individuals with higher physical fitness levels, particularly in healthy individuals compared to those with type 2 diabetes. In mice, exercise training increased TNFRSF9 expression and enhanced mitochondrial content in subcutaneous adipose tissue. TNFRSF9 has also been associated with long-term disease severity in Parkinson's disease, with increased levels of TNFRSF9 correlating with more severe motor and cognitive symptoms. In autoimmune Addison's disease, altered biomarkers for cardiovascular disease and inflammation, including TNFRSF9, have been observed. Additionally, TNFRSF9 has been studied in the context of immunotherapy, as agonism of TNFRSF9 can enhance immune cell function and has been investigated as a potential treatment for cancer. TNFRSF9 stimulation has been shown to induce an inflammatory and immunosuppressive phenotype in neutrophils in ovarian cancer. Overall, TNFRSF9 has diverse applications in various disease contexts and immune responses.